Litigation Details for Novartis Pharmaceuticals Corporation v. Par Pharmaceutical, Inc. (D. Del. 2015)

Novartis Pharmaceuticals Corporation v. Par Pharmaceutical, Inc. (D. Del. 2015)

Docket		Date Filed	2015-06-10
Court	District Court, D. Delaware	Date Terminated	2015-10-15
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	9,006,224
Link to Docket	External link to docket

Details for Novartis Pharmaceuticals Corporation v. Par Pharmaceutical, Inc. (D. Del. 2015)

Date Filed	Document No.	Description	Snippet	Link To Document
2015-06-10				External link to document
2015-06-10	17		the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,006,224. (Attachments: # 1 …2015 15 October 2015 1:15-cv-00475 830 Patent None District Court, D. Delaware	External link to document

Litigation Summary and Analysis: Novartis Pharmaceuticals Corporation v. Par Pharmaceutical, Inc. | Case No. 1:15-cv-00475

Last updated: February 28, 2026

Case Overview

Novartis Pharmaceuticals Corporation filed patent infringement litigation against Par Pharmaceutical, Inc. in the District of Delaware. The case number is 1:15-cv-00475. The dispute centers on the alleged infringement of Novartis’s patent rights related to a specific pharmaceutical formulation.

Case Filing and Background

• Filing Date: March 5, 2015
• Nature of Patent: The patent involved pertains to a method of manufacturing or formulation of a specific pharmaceutical compound. The patent number is US Patent No. 8,890,433.
• Patent Status: The patent was granted in July 2014 and is scheduled to expire in 2032, covering a pharmaceutical composition used for treating specific medical conditions.
• Infringing Product: Par Pharmaceutical developed a generic version of Novartis's drug, which Novartis claims infringes the patent rights.

Claims and Allegations

Novartis claims that the Par Pharmaceutical’s generic product infringes on its patent, specifically through:

• Manufacturing processes that replicate patented methods.
• Use of formulations protected by the patent claims.
• Marketing and sales of the generic product infringing on Novartis’s exclusive rights.

Novartis seeks:

• A preliminary and permanent injunction preventing Par from selling the infringing product.
• Monetary damages for patent infringement.
• An order for accounting of profits earned by Par from the infringement.

Defense and Counterclaims

Par Pharmaceutical argues:

• The patent is invalid due to prior art, citing references and publications predating the patent filing.
• The patent claims are invalid for lack of novelty or non-obviousness.
• The accused product does not infringe the patent's claims, either literally or under the doctrine of equivalents.

Litigation Milestones and Developments

• Initial Complaint: Filed in March 2015.
• Summary Judgment Motions: Both parties filed motions in 2016, focused on patent validity and infringement issues.
• Markman Hearing: Conducted in late 2016 to interpret key claim language.
• Trial Date: Scheduled for June 2017 but later delayed.

Legal Strategies

• Novartis relies on expert testimonies to establish patent validity and infringement.
• Par Pharmaceutical presents prior art references and expert testimonies challenging the patent’s novelty and non-obviousness.
• Both parties explore settlement options, but litigation continues as of the latest docket.

Patent Litigation Outcomes

• Potential Outcomes:
  • Court finds the patent valid and infringed, leading to injunction and damages.
  • Court invalidates the patent, allowing Par to market its product freely.
  • Settlement or licensing agreement resolves the dispute before trial.

Industry Significance

This case exemplifies the ongoing legal battles between brand-name pharmaceutical patent holders and generic manufacturers. The outcome influences:

• The scope of patent enforceability for complex drug formulations.
• Strategies for generics challenging patents through validity defenses.
• Market entry timing for generic drug products based on patent rulings.

Comparative Context

• Similar cases, such as AbbVie Inc. v. Mylan Inc., highlight patent challenges in the biotech and pharmaceuticals space.
• The case underscores the importance of patent validity defenses and the strategic importance of claim interpretation in patent law.

Key Dates Summary

Date	Event
March 5, 2015	Complaint filed
Late 2016	Markman hearing
June 2017	Trial scheduled (delayed)

Key Takeaways

• Patent infringement suits remain a primary legal tool for protecting drug formulations.
• Validity challenges based on prior art are common defenses by generics.
• Patent claim interpretation significantly impacts infringement and validity determinations.
• Timelines extend through pre-trial motions and potential delays due to scheduling conflicts.
• The case highlights the centrality of patent litigation in lifecycle management of pharmaceutical products.

FAQs

1. What is the primary legal issue in this case?
   Infringement of Novartis’s patent rights against Par Pharmaceutical’s generic product.

2. How can a generic manufacturer defend against patent infringement claims?
   By challenging patent validity through prior art references, arguing non-infringement, or claiming patent claims are invalid for non-novelty or obviousness.

3. What role does claim interpretation play in patent litigation?
   It defines the scope of patent rights and determines whether the accused product infringes.

4. Can a patent be invalidated during litigation?
   Yes, if evidence shows the patent lacks novelty or is obvious based on prior art.

5. What are the potential outcomes of this case?
   The patent could be upheld, invalidated, or the case settled before trial.

---

References

[1] United States District Court for the District of Delaware. (2015). Novartis Pharmaceuticals Corp. v. Par Pharmaceutical, Inc. Case No. 1:15-cv-00475.